Tomoya Miura1, Daisuke Ban2, Shinji Tanaka3, Kaoru Mogushi4, Atsushi Kudo1, Satoshi Matsumura1, Yusuke Mitsunori1, Takanori Ochiai1, Hiroshi Tanaka4, Minoru Tanabe1. 1. Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan. 2. Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: d-ban.msrg@tmd.ac.jp. 3. Department of Molecular Oncology, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan. 4. Department of Bioinformatics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
Abstract
BACKGROUND: Although hepatocellular carcinoma (HCC) is mostly a lower intensity lesion in the hepatobiliary phase on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging, some HCCs were shown as a higher intensity lesion (high HCC). This study aimed to reveal the clinicopathological and biological properties of high HCC. METHODS: Patients who underwent curative hepatectomy as the first treatment for HCC were included. HCC was defined as high HCC if the ratio between the signal intensity of the HCC and the background liver was greater than or equal to 1.0. We retrospectively performed clinicopathological and global gene expression analyses. RESULTS: Of the 77 patients, 14 had high HCC. Serum protein induced by vitamin K absence or antagonist II levels in high HCC were lower, and the high HCCs were well differentiated. The 3-year disease-free survival rates in high HCC and low HCC patients were 90% and 54%, respectively (P = .035). Overall survival did not differ significantly. Global gene expression analysis revealed that SLCO1B3 was upregulated in high HCC. CONCLUSIONS: Clinicopathological analysis revealed low-grade malignancy in high HCCs compared with low HCCs. The expression of SLCO1B3 was key to the hyperintensity in the hepatobiliary phase of ethoxybenzyl-diethylenetriamine pentaacetic acid magnetic resonance imaging.
BACKGROUND: Although hepatocellular carcinoma (HCC) is mostly a lower intensity lesion in the hepatobiliary phase on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging, some HCCs were shown as a higher intensity lesion (high HCC). This study aimed to reveal the clinicopathological and biological properties of high HCC. METHODS:Patients who underwent curative hepatectomy as the first treatment for HCC were included. HCC was defined as high HCC if the ratio between the signal intensity of the HCC and the background liver was greater than or equal to 1.0. We retrospectively performed clinicopathological and global gene expression analyses. RESULTS: Of the 77 patients, 14 had high HCC. Serum protein induced by vitamin K absence or antagonist II levels in high HCC were lower, and the high HCCs were well differentiated. The 3-year disease-free survival rates in high HCC and low HCC patients were 90% and 54%, respectively (P = .035). Overall survival did not differ significantly. Global gene expression analysis revealed that SLCO1B3 was upregulated in high HCC. CONCLUSIONS: Clinicopathological analysis revealed low-grade malignancy in high HCCs compared with low HCCs. The expression of SLCO1B3 was key to the hyperintensity in the hepatobiliary phase of ethoxybenzyl-diethylenetriamine pentaacetic acid magnetic resonance imaging.
Authors: Harrison X Bai; Ashley M Lee; Li Yang; Paul Zhang; Christos Davatzikos; John M Maris; Sharon J Diskin Journal: Br J Radiol Date: 2016-02-11 Impact factor: 3.039
Authors: Taiga Wakabayashi; Farid Ouhmich; Cristians Gonzalez-Cabrera; Emanuele Felli; Antonio Saviano; Vincent Agnus; Peter Savadjiev; Thomas F Baumert; Patrick Pessaux; Jacques Marescaux; Benoit Gallix Journal: Hepatol Int Date: 2019-08-31 Impact factor: 9.029
Authors: Mariarosaria Incoronato; Marco Aiello; Teresa Infante; Carlo Cavaliere; Anna Maria Grimaldi; Peppino Mirabelli; Serena Monti; Marco Salvatore Journal: Int J Mol Sci Date: 2017-04-12 Impact factor: 5.923
Authors: Marcello Mancini; Paul Summers; Francesco Faita; Maurizia R Brunetto; Francesco Callea; Andrea De Nicola; Nicole Di Lascio; Fabio Farinati; Amalia Gastaldelli; Bruno Gridelli; Peppino Mirabelli; Emanuele Neri; Piero A Salvadori; Eleni Rebelos; Claudio Tiribelli; Luca Valenti; Marco Salvatore; Ferruccio Bonino Journal: World J Hepatol Date: 2018-02-27
Authors: Robin W Jansen; Paul van Amstel; Roland M Martens; Irsan E Kooi; Pieter Wesseling; Adrianus J de Langen; Catharina W Menke-Van der Houven van Oordt; Bernard H E Jansen; Annette C Moll; Josephine C Dorsman; Jonas A Castelijns; Pim de Graaf; Marcus C de Jong Journal: Oncotarget Date: 2018-04-13